‘Fishing’ for therapies to ‘net’ cost-effective benefits

Ademi Z Ofori-Asenso R Zomer E , et al. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. Eur J Prev Cardiol, Epub ahead of print 10 January 2020. DOI: 10.1177/2047487319896648.

Aung T Halsey J Kromhout D , et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: Meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol 2018; 3: 225–234.

Bhatt DL Steg PG Miller M , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380: 11–22.

Amarin Pharma Inc. Vascepa: Highlights of prescribing information. Bridgewater, NJ: Amarin Pharma, 2019.

Vascepa (icosapent ethyl), www.goodrx.com/vascepa (2020, accessed 11 January 2020).

Zomer E Liew D Tonkin A , et al. The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. Int J Cardiol 2019; 285: 1–5.

Fonarow GC Keech AC Pedersen TR , et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2017; 2: 1069–1078.

Gao L Moodie M Li SC. The cost-effectiveness of omega-3 polyunsaturated fatty acids – the Australian healthcare perspective. Eur J Intern Med 2019; 67: 70–76.

Lovaza (omega-3-acid ethyl esters), www.goodrx.com/lovaza (2020, accessed 18 January 2020).

Cholesterol Treatment Trialists' Collaboration Fulcher J O’Connell R , et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385: 1397–1405.

Cannon CP Blazing MA Giugliano RP , et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–2397.

Sabatine MS Giugliano RP Keech AC , et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

Schwartz GG Steg PG Szarek M , et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097–2107.

ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563–1574.

Superko HR Zhao XQ Hodis HN , et al. Niacin and heart disease prevention: Engraving its tombstone is a mistake. J Clin Lipidol 2017; 11: 1309–1317.

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999; 354: 447–455.

Yokoyama M Origasa H Matsuzaki M , et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090–1098.

Kodera S Morita H Kiyosue A , et al. cost-effectiveness of statin plus eicosapentaenoic acid combination therapy for cardiovascular disease prevention in Japanese patients with hypercholesterolemia – an analysis based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS). Circ J 2018; 82: 1076–1082.

Kemp A. Update on Phase III STRENGTH trial for Epanova in mixed dyslipidaemia, www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020.html (2020, accessed 20 January 2020).

Budoff M Brent Muhlestein J Le VT , et al. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. Clin Cardiol 2018; 41: 13–19.

Budhoff MJ. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy – EVAPORATE, www.acc.org/latest-in-cardiology/clinical-trials/2019/11/15/17/46/evaporate?promo_creative=/latest-in-cardiology/clinical-trials/2019/11/15/17/46/evaporate&promo_position=image_slider_1&promo_id=Latest-in-Cardiology&promo_name=featured_content#references-for-article (2019, accessed 19 January 2020).

Orringer CE Jacobson TA Maki KC. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol 2019; 13: 860–872.

Arnett DK Blumenthal RS Albert MA , et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140: e596–e646.

Kazi DS Moran AE Coxson PG , et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 2016; 316: 743–753.

Kodera S Morita H Kiyosue A , et al. Cost-effectiveness of PCSK9 inhibitor plus statin in patients with triple-vessel coronary artery disease in Japan. Circ J 2018; 82: 2602–2608.

Fonarow GC van Hout B Villa G , et al. Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. JAMA Cardiol 2019; 4: 691–695.

Grundy SM Stone NJ Bailey AL , et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73: e285–e350.